NEW YORK (GenomeWeb News) – Cancer genome analysis firm Personal Genome Diagnostics said today that it will collaborate with Blueprint Medicines to search for novel kinase targets for cancer drugs.

Personal Genome Diagnostics will use exome sequencing as well as its own proprietary digital karyotyping technology, which it licensed from Johns Hopkins, to analyze copy number changes in cancer genomes.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Fareed Zakaria writes that instead of focusing solely on STEM-related courses, students would do well to pursue the liberal arts if they want to be technology innovators.

A Harvard Business Review study found four major patterns of gender biases and added that black and Latina scientists further had to navigate racial stereotypes.

In PLOS this week: variant linked to canine cleft lip, new compression tool, and more.

GNC will start using DNA testing to authentic the presence of plants included in its labels, following an agreement with the New York Attorney General.